MECOM and chronic myelogenous leukemia, BCR-ABL1 positive: In LSK fraction, although nilotinib-treated Evi1+/GFPBCR–ABLtg/− mice showed the reduced number of Evi1-low LSK cells in BM compared with vehicle-treated Evi1+/GFPBCR–ABLtg/− mice, that of Evi1-high LSK cells had no change irrespective of nilotinib treatment, which implied nilotinib resistance of Evi1-high CML cells (Figure 3e).